# A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

> **NCT02418559** · PHASE1 · COMPLETED · sponsor: **Janssen Infectious Diseases BVBA** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-63623872 (300 mg)
- **DRUG:** JNJ-63623872 (600 mg)
- **DRUG:** JNJ-63623872 (1200 mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02418559
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418559, "A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02418559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*